Profile data is unavailable for this security.
About the company
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
- Revenue in USD (TTM)232.28m
- Net income in USD-6.39m
- Incorporated2000
- Employees408.00
- LocationDynavax Technologies Corp2100 Powell Street, Suite 720EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 848-5100
- Fax+1 (510) 848-1327
- Websitehttps://www.dynavax.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vir Biotechnology Inc | 86.18m | -615.06m | 1.41bn | 587.00 | -- | 0.8806 | -- | 16.38 | -4.59 | -4.59 | 0.6425 | 11.80 | 0.0365 | -- | -- | 146,814.30 | -26.06 | -0.6081 | -30.49 | -0.7192 | 96.79 | -- | -713.76 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.42bn | 297.00 | 235.68 | 3.29 | 131.16 | 4.72 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
Arcus Biosciences Inc | 117.00m | -307.00m | 1.43bn | 577.00 | -- | 2.57 | -- | 12.20 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Neumora Therapeutics Inc | 0.00 | -235.93m | 1.47bn | 124.00 | -- | 3.13 | -- | -- | -2.33 | -2.33 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Xencor Inc | 168.34m | -126.09m | 1.49bn | 280.00 | -- | 2.20 | -- | 8.83 | -2.10 | -2.10 | 2.79 | 10.96 | 0.1872 | -- | 8.36 | 601,207.10 | -14.04 | -3.70 | -15.30 | -4.12 | -- | -- | -75.00 | -15.92 | -- | -- | 0.0304 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Morphic Holding Inc | 0.00 | -161.25m | 1.50bn | 124.00 | -- | 2.26 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
Day One Biopharmaceuticals Inc | 0.00 | -188.92m | 1.50bn | 155.00 | -- | 4.32 | -- | -- | -2.37 | -2.37 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.11 | -- | -55.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Soleno Therapeutics Inc | 0.00 | -38.99m | 1.51bn | 33.00 | -- | 9.07 | -- | -- | -2.97 | -2.97 | 0.00 | 4.97 | 0.00 | -- | -- | 0.00 | -37.64 | -53.90 | -41.40 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
Protagonist Therapeutics Inc | 60.00m | -78.96m | 1.53bn | 112.00 | -- | 4.47 | -- | 25.50 | -1.47 | -1.47 | 1.06 | 5.83 | 0.1981 | -- | 11.56 | 535,714.30 | -26.06 | -35.90 | -28.53 | -41.36 | -- | -- | -131.59 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Dynavax Technologies Corp | 232.28m | -6.39m | 1.54bn | 408.00 | -- | 2.44 | -- | 6.61 | -0.0733 | -0.0733 | 1.65 | 4.80 | 0.2343 | 0.89 | 2.50 | 569,323.50 | -0.6444 | 4.16 | -0.7216 | 5.71 | 78.40 | 64.83 | -2.75 | 9.19 | 12.96 | -- | 0.2636 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Kura Oncology Inc | 0.00 | -168.09m | 1.57bn | 142.00 | -- | 3.11 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
ADMA Biologics Inc | 258.22m | -28.24m | 1.58bn | 624.00 | -- | 11.39 | -- | 6.11 | -0.1263 | -0.1263 | 1.14 | 0.5981 | 0.7621 | 1.01 | 12.03 | 413,806.10 | -8.33 | -24.80 | -9.60 | -28.00 | 34.44 | 17.02 | -10.94 | -51.31 | 1.69 | 0.924 | 0.4913 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
Novocure Ltd | 525.66m | -192.74m | 1.59bn | 1.45k | -- | 4.43 | -- | 3.03 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
Taro Pharmaceutical Industries Ltd | 610.83m | 45.70m | 1.60bn | 1.55k | 34.91 | 0.8969 | 20.10 | 2.61 | 1.22 | 1.22 | 16.25 | 47.33 | 0.2854 | 1.45 | 2.76 | 393,068.20 | 2.14 | 1.85 | 2.59 | 2.21 | 48.02 | 56.82 | 7.48 | 6.99 | 3.03 | -- | 0.00 | 0.00 | 2.07 | -2.85 | -56.33 | -34.53 | -7.64 | -- |
Tilray Brands Inc | 743.25m | -351.95m | 1.63bn | 1.60k | -- | 0.4839 | -- | 2.19 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 20.72m | 15.86% |
Federated Global Investment Management Corp.as of 31 Dec 2023 | 11.36m | 8.70% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 9.50m | 7.27% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 8.95m | 6.85% |
Deep Track Capital LPas of 31 Dec 2023 | 7.09m | 5.43% |
Chicago Capital LLCas of 31 Mar 2024 | 5.64m | 4.32% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 4.03m | 3.09% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 3.30m | 2.53% |
Eventide Asset Management LLCas of 31 Dec 2023 | 2.89m | 2.22% |
Geode Capital Management LLCas of 31 Dec 2023 | 2.82m | 2.16% |